Antigenics Cancer Company Intelligence Report Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip ...more

Market Briefing September 2005

Anticancer Cancer Company Intelligence Report Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip ...more

Market Briefing September 2005

Anosys Cancer Company Intelligence Report Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip ...more

Market Briefing September 2005

Anormed Cancer Company Intelligence Report Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip ...more

Market Briefing September 2005

U.S. Market for Gastrointestinal Pharmaceuticals The total U.S. market for gastrointestinal disorder treatments was estimated at $16.1 billion for 2004. ...more

Market Study September 2005

Pipeline Insight: Antidyslipidemics - The Power of Two Datamonitor estimates that there are 267m people in the seven major markets with total cholesterol ...more

Management Report August 2005

Tysabri - Can Efficacy of VLA-4 Mechanism Overcome Safety Concerns? Tysabri was voluntarily withdrawn from the multiple sclerosis market in February 2005 following two cases ...more

Market Study August 2005

PharmaVitae 2005: Altana Global Analysis This company analysis examines Altana's market position and future outlook. ...more

Market Study August 2005

Commercial Insight: Antibacterials - Pharma Strikes Antibac Rapid uptake of products focused on drug-resistant infections, such as Pfizer's Zyvox (linezolid), has ...more

Management Report August 2005

Commercial Insight: ADHD - Strattera Will Reign Supreme When Branded Stimulants Slump With annual revenues of over $2.6 billion in 2004, and a compound annual growth rate of 36. ...more

Management Report July 2005

PharmaVitae 2005: Genzyme Global Analysis This analysis examines the current position and future outlook for Genzyme in the biotechnology sector. ...more

Market Study July 2005

Commercial Insight: Cytotoxics - Generic Adversity Facing Major Cytotoxics There is a plethora of cytotoxics on the market but only a few dominate in terms of sales. ...more

Management Report July 2005

PharmaVitae 2005: Johnson & Johnson Global & US Analysis This analysis examines the current position and future outlook for J&J in the ethical pharmaceutical ...more

Management Report July 2005

PharmaVitae 2005: Johnson & Johnson Global Analysis This Analysis examines the current position and future outlook for J&J in the ethical pharmaceutical ...more

Market Study July 2005

PharmaVitae 2005: Shire Global & US Analysis This analysis examines the current position and future outlook for Shire Pharmaceuticals in the ethical ...more

Market Study July 2005

PharmaVitae 2005: Shire Global Analysis This analysis examines the current position and future outlook for Shire Pharmaceuticals in the ethical ...more

Market Study July 2005